OncoMed Studying Vantictumab in HER2-Negative Breast Cancer; Exploring Predictive Biomarkers | GenomeWeb

OncoMed Pharmaceuticals this week announced that it has launched a Phase Ib trial to investigate the use of its Wnt pathway-targeting antibody vantictumab in combination with paclitaxel as a potential treatment for breast cancer.

The Phase Ib study is one of three trials for vantictumab that OncoMed is planning to launch by year end as part of a collaboration with Bayer Pharma. Researchers will also look for predictive response markers that could be used to identify best responders to vantictumab.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.